Physician profile
James M Jiunta
NPI 1184618563
$3,364.67
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $610 · 2021: $992 · 2022: $646 · 2023: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $709.66 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $526.15 | 2019-2022 | |
| Amgen INC. | $379.41 | 2019-2023 | Repatha |
| Abbvie INC. | $293.67 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $265.46 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $208.53 | 2019-2022 | |
| Lilly USA, LLC | $121.94 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $105.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $102.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.05 | 2019-2023 | Tradjenta, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $68.39 | 2021-2022 | |
| Pfizer INC. | $64.77 | 2021-2023 | |
| Glaxosmithkline, LLC. | $55.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.21 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.89 | 2021 | |
| Exact Sciences Corporation | $35.51 | 2023 | Cologuard Collection Kit |
| Biodelivery Sciences International, INC. | $31.21 | 2020-2021 | |
| Abbott Laboratories | $30.71 | 2022-2023 | Freestyle Libre 3 |
| Adamas Pharmaceuticals, INC. | $26.66 | 2021 | |
| Ibsa Pharma INC. | $22.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.23 | 2021 | |
| Shield Therapeutics INC | $13.98 | 2023 | Accrufer |
| Astellas Pharma US INC | $13.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.82 | 2019 | |
| Allergan, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jiunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.